Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

This study is testing combinations of medications that include anlotinib (a drug that cuts off blood supply to tumors) for women with hormone receptor-positive, HER2-negative breast cancer that has spread to other parts of the body and is no longer responding to standard treatments. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have hormone receptor-positive (HR+), HER2-negative breast cancer that has spread (metastatic) - You have already tried multiple lines of treatment and have no remaining standard options - You have measurable disease that can be tracked by imaging - Your general health score (ECOG) is 0 or 1, and you are expected to survive at least 3 months **You may NOT be eligible if...** - You still have standard treatment options available - Your cancer is HER2-positive - You are in poor general health Talk to your doctor to see if this trial is right for you.